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Abstract––Novel 2-deoxo-2-phenyl-5-deazaflavins and 2-deoxo-2-phenylflavin-5-oxides were prepared as a new 
class of antitumor agents and showed significant antitumor activities against NCI-H 460, HCT 116, A 431, 
CCRF-HSB-2, and KB cell lines. In vivo investigation, 2-deoxo-10-methyl-2-phenyl-5-deazaflavin exhibited the 
effective antitumor activity against A 431 human adenocarcinoma cells transplanted subcutaneously into nude 
mouse. Furthermore, AutoDock study has been done by binding of the flavin analogs into PTK pp60c-src, where a 
good correlation between their IC50 and AutoDock binding free energy was exhibited. In particular, 
2-deoxo-2-phenylflavin-5-oxides exhibited the highest potential binding affinity within the binding pocket of PTK. 
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1. Introduction 
 
During the last three decades there has been considerable interest in synthesis, functional elucidation, and 
biological evaluation of 5-deazaflavins {5-deazaisoalloxazines, pyrimido[4,5-b]quinoline-2,4(3H,10H)-diones}. 
Actually, 5-deazaflavins have attracted great interest because of the first synthesis as potential flavin antagonists 
of flavin models1 and of the discovery that they serve as co-factors for several flavin catalyzed reactions2 (Scheme 
1). They also have the potent broad-spectrum activity against coccidiosis.3 Recently, we have preliminary reported 
the selective protein kinase C (PKC) inhibitory activities of 5-deazaflavins and 2-deoxo-2-phenyl-5-deazaflavins 
{2-phenylpyrimido[4,5-b]quinolin-4(10H)-ones}, and their effective growth inhibition against cancer cell lines 
such as A 431 cells and HT 1080 cells.4 Antitumor activities of nitro-5-deazaflavin-pyrrolecarboxamide hybrid 
molecules5 and 5-amino-5-deazaflavin derivatives revealed potential inhibitory activity against L 1210 or KB 
cells.6  In addition, cytotoxicities of the nitro-5-deazaflavins were evaluated in vitro for hypoxic and oxic Chinese 
hamster cells (V79). The 6- and 8-nitro derivatives were generally more toxic against hypoxic cells than oxic cells 
and showing marked hypoxic selectivity.7  
 
 
 
Computer-aided drug design tools can generate many useful and powerful models that explain structure-activity 
relationships (SAR) observations in a quantitative manner. Using a model with a given structure, medicinal 
chemists can compute the activity of a molecule.8 Very recently, the impressive technological advances in areas 
such as structural characterization of biomacromolecules, computer sciences and molecular biology have made 
rational drug design feasible.9 The explosion of genomic, proteomic, and structural information has provided 
hundreds of new targets and opportunities for future discovery process of lead drug.10 Many new protein structures 
of pharmaceutical interest have been elucidated, and a substantial number of those proteins contain an embedded 
inhibitor. Meanwhile, several drugs that were designed by intensive use of computational methods are currently 
under investigation through clinical trials.11 AutoDock is one of the most widely used docking programs in 
computational binding studies. It is said to offer a reasonable result in comparison with other methods that 
specialize either in fast database searches or in computationally intensive calculations.12 
The main goal of this study is the development of potential inhibitors synthesized newly, e.g. 5-deazaflavins, 
flavins, flavin-5-oxides, and their analogs as antitumor agents, based on molecular modeling with the 
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investigation of SAR between new inhibitors and protein tyrosine kinase (PTK). Thereupon, 
2-deoxo-2-phenylflavin-5-oxide derivatives were designed and synthesized for the aim to get stronger binding 
affinity and more hydrogen bonds to the binding pocket of the PTK due to the polar part of the N-oxide moiety. In 
the present paper, we describe the preparation of 2-deoxo-2-phenyl-5-deazaflavins and 
2-deoxo-2-phenylflavin-5-oxides and their antitumor activities, and also the AutoDock study for new inhibitors 
docked into the binding pocket of PTK. In this study, compounds having potential antitumor and PTK inhibitory 
activities, i.e., IC50 values less than 25 µM, were docked into the binding pocket of PTK using AutoDock 3.05 
program.  
 
2. Results and Discussion 
2.1. Chemistry 
The required 6-N-monoalkylanilino-2-phenylpyrimidin-4(3H)-ones (1a–j), which were used as precursors for 
synthesis of 2-deoxo-2-phenyl-5-deazaflavins (2a–g) and 2-deoxo-2-phenylflavin-5-oxide (3a–i), were synthesized 
by fusion of 6-chloro-2-phenylpyrimidin-4(3H)-one with appropriate N-alkyl anilines at 180–200 °C under nitrogen 
atmosphere for 0.5–5 hours according to the known procedure13 as shown in  Scheme 2. The commercially 
unavailable N-monomethylated anilines were synthesized from appropriate aniline derivatives in 2-steps, by reaction 
of anilines with ethyl formate under reflux for 15 hours to get the N-arylformamides and followed by reduction 
using LiAlH4 in THF to afford the corresponding N-monomethylated anilines.14  
The intended 10-alkylated 2-deoxo-2-phenyl-5-deazaflavins (2a–g) were prepared by reaction of 1a, b, d–h with 
Vilsmeier reagent (N,N-dimethylformamide–phosphoryl chloride) at 90 °C for 1–4 hours, and the 10-unsubstituted 
derivatives (2h–j) were prepared from 6-anilino-2-phenylpyrimidin-4(3H)-ones15 in the same conditions of 
Vilsmeier reaction. This synthetic method is an useful preparation for 5-deazaflavins from 6-(N-monoalkylanilino) 
uracils.16 The 10-methyl-2-phenylpyrimido[4,5-b]quinolin-4(10H)-one (2a) was also prepared by methylation of 
2-phenylpyrimido[4,5-b]quinolin-4(10H)-one (2h) with excess methyl iodide in the presence of anhydrous 
potassium carbonate in DMF at room temperature in 80% yield. On the other hand, 2-deoxo-2-phenylflavin-5-oxide 
(3a–i) were prepared by nitrosative cyclization of 6-N-monoalkylanilino-2-phenylpyrimidin-4(3H)-ones (1a–h, j) 
with excess NaNO2 in AcOH at 10–15 °C for 2–5 hours. However, such cyclization of 1i was difficult due to the 
peri steric hindrance between the ethyl at the N-ethyl and the ortho methyl of aniline moiety.  
The structures of the products 1a–j were confirmed in particular by the presence of an equivalent proton resonance 
at the 5-position as a singlet signal at δH 4.8–5.3 in 1H NMR spectra and by the presence of the C5 carbon signal at 
δC 86–87 in 13C NMR spectra (Table 1). The cyclized 2-deoxo-2-phenyl-5-deazaflavins (2a–j) showed a 
characteristic singlet signal in the lower field at δH 9.2–9.4 due to the proton at the 5-position of 2a–j and a signal at 
δC 137–141 due to the carbon at the 5-position. It is implying that the 5-position of 2a–j is the most 
electron-deficient methine and very reactive to nucleophiles. Whereas, the 2-deoxo-2-phenylflavin-5-oxides (3a–i) 
showed no such signals at the 5-position. On the other hand, the UV absorption spectra of the anilinopyrimidones 
(1a–j) showed one absorption maximum at 253–257 nm together with an absorption maximum as shoulder at 
272–274 nm. Whereas, the 10-alkylated deazaflavins (2a–g) showed four absorption maxima at 283–297, 336–355, 
414–431 and 433–456 nm together with an absorption maximum as shoulder at 262–288 nm, and the 
10-unsubstituted deazaflavins (2h–i) also showed three absorption maxima at 279–290, 364–370, and 374–385 nm, 
which were observed with hypsochromic shift in the region of the longest wavelength in comparison with those of 
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2a–g,, together with an absorption maximum as shoulder at 254–256 nm. In contrast with the above UV absorption 
spectra, the 2-deoxo-2-phenylflavin-5-oxides (3a–i) exhibited the absorptions in the region of longer wavelength, 
i.e., four absorption maxima at 303–312, 362–373, 470–496 and 500–528 nm together with an absorption maximum 
as shoulder at 292–302 nm. All compounds of 3a–i showed red color owing to the presence of absorption maximum 
at ca. 515 nm in the longest wavelength.  
 
 
 
Scheme 2.  General method for the preparation of 6-(N-alkylanilino)-2-phenylpyrimidin-4(3H)-ones(1a–j), 
2-deoxo-2-phenyl-5-deazaflavins (2a–j), and 2-deoxo-2-phenylflavin-5-oxides (3a–i). 
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2.2. In vitro antitumor activities of deazaflavin and flavin analogs against human tumor cell lines  
The synthesized compounds 2a-j and 3a-i were tested in vitro for growth inhibitory activities against various 
cultured tumor cell lines. Five human tumor cell lines including human lung cancer cell line (NCI-H 460), human 
colon carcinoma cell line (HCT 116), human adenocarcinoma cell line (A 431), human T-cell acute 
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lymphoblastoid leukemia cell line (CCRF-HSB-2) and human oral epidermoid carcinoma cell line (KB) were 
used, and the antitumor agents of Ara-C, cisplatin and adriamycin were also used as positive controls in this study. 
As can be seen from Table 2, many compounds of flavin analogs such as 2-deoxo-2-phenyl-5-deazaflavins (2) and 
2-deoxo-2-phenylflavin-5-oxides (3) have been found to show fairly good antitumor activities. Although the 
tested flavin analogs showed a little poor antitumor activities than that of cisplatin against NCI-H 460 cell line, 
their activities for the compounds 2a, 2c, 3a, and 3f against HCT 116 cell line were higher than cisplatin. 
Especially, compound 3f (IC50: 0.72 µM ) exhibited 3 folds more potent antitumor activity than that of cisplatin 
(IC50: 2.23 µM). Further, against A 431 cell line they showed less antitumor activities in comparison with 
adriamycin. Though it is also inferior to the antitumor activity of Ara-C (IC50: 0.15 µM), many compounds 
showed 0.5–2.0 µM potential growth inhibitory activities against CCRF-HSB-2 cell line.  In case against KB 
cell line, many compounds showed 0.5–5.0 µM potential growth inhibitory activities and the compounds 2e and 
2g (IC50: 0.5 µM) exhibited more potent antitumor activities than that of Ara-C (IC50: 0.70 µM).  
 
 
 
2.3. In vivo antitumor activity against subcutaneously transplanted human adenocarcinoma A 431 
xenograft  
In vivo research has an advantage to discover drugs as the nature and properties of a chemical tool cannot be 
 8 
considered independently. Therefore, the antitumor activities of compounds 2a and 2b against subcutaneously 
transplanted human adenocarcinoma A 431 xenograft in mice were measured, and the tumor volume and body 
weights of mice were evaluated. Thus the human adenocarcinoma A 431 was subcutaneously transplanted into 
BALB/c nude mice, and the administration of test compounds was started on the day (day 1) when the mice show 
tumor growth in the 100–300 mm3 range. Since the test compounds prepared here showed poor solubility in water, 
the administrations were done by intratumoral (i.t.), intraperitoneal (i.p.) or oral (p.o.) methods. Table 3 shows the 
antitumor activity 10-methyl derivative (2a) and 10-ethyl derivative (2b) of 2-deoxo-2-phenyl-5-deazaflavin 
against A 431 human adenocarcinoma cells. After the compound (2a, 25 mg/kg, i.t.) was given into the tumor 
cells by intratumoral administration, the tumor growth was inhibited significantly as can be seen in the T/C%, 
namely, the tumor volume was reduced to 57.2% after 17 days of the administration.  But the similar 
intratumoral administration of compound (2b) did not inhibit the tumor growth. The antitumor activity of 
compound (2a, 100 mg/kg, i.p.) was further investigated by intraperitoneal administration. After the compound 
(2a) was given into the tumor cells by i.p., the tumor volume was reduced to 53.4% after 10 days of the 
administration, whereas staurosporine (1 mg/kg, i.p.) similarly reduced to 84.9% the tumor volume. The 
staurosporine was used only 1 mg/kg as a positive control because it was too toxic. Figure 1 shows A 431 tumor 
volume implanted into nude mouse treated with chemicals (i.p.) after several days. Depending on the gradual 
deduction of the tumor volume with the progress of time after the initial administration, the more effectual 
antitumor activity of 2-deoxo-10-methyl-2-phenyl-5-deazaflavin (2a, 100 mg/kg, i.p.) than that of staurosporine 
was observed. Moreover, the antitumor activity of compound (2a, 75 and 100 mg/kg, p.o.) was investigated by 
oral administration as shown in Table 3. After the compound (2a) was given by p.o., the tumor volume was 
reduced to 97.6% (dose: 75 mg/kg) and 51.8% (dose: 150 mg/kg) after 18 days of the administration, whereas 
staurosporine reduced to 72.9% the tumor volume. Figure 2 also shows A 431 tumor volume implanted into nude 
mouse treated with chemicals (p.o.) after several days. Depending on the gradual deduction of the tumor volume 
with the progress of time after the initial administration, the more effectual antitumor activity of 
2-deoxo-10-methyl-2-phenyl-5-deazaflavin (2a, 150 mg/kg, p.o.) than that of staurosporine (1 mg/kg, p.o) was 
observed, but the dose of 75 mg/kg was insufficient antitumor activity. 
Accordingly, the antitumor activity of compound 2a in vivo was shown to be more effective than compound 2b 
though compound 2a exhibited weaker activity than that of compound 2b against A431 tumor cells in vitro as 
shown in Table 2.  There is no fixed rule that the compound, which has biological activity in vitro, must exhibit 
the same effect in vivo. For example, the nonselective protein kinase inhibitor, staurosporine, did not exhibit any 
antitumor activity in vivo though it has much greater antiproliferative activity than UCN-01 
(7-hydroxy-staurosporine) in vitro.17 
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Figure 1.  A 431 tumor volume implanted into nude mouse treated with chemicals (i.p.) after several days. 
A 431 cells were implanted subcutaneously into nude mice and the administration was started on the day when the 
mice show tumor growth in the 100–300 mm3 range. 
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Figure 2.  A 431 tumor volume implanted into nude mouse treated with chemicals (p.o.) after 
several days. A 431 cells were implanted subcutaneously into nude mice and the administration 
was started on the day when the mice show tumor growth in the 100–300 mm3 range. 
    
2.4. Molecular docking study  
The computer simulated automated docking studies were performed using the widely distributed molecular 
docking software, AutoDock 3.05.18  The AutoDock study of 2-deoxo-2-phenyl-5-deazaflavins (2a–j), 
2-deoxo-2-phenylflavin-5-oxides (3a–i), and the computationally designed 3j and 2-deoxo-2-phenylflavins (4a–j) 
was carried out, and they were docked within the protein tyrosine kinase (PTK pp60c-src, PDB code: 1skj). As 
shown in Table 4, their AutoDock binding free energies (ΔGb kcal/mol) and inhibition constants (Ki) were 
obtained. Among them, all flavin-5-oxides (3a–j) exhibited the lowest free energy between –7.84 and –5.95 
kcal/mol. In other words, they possess the highest potential binding affinity into the binding site of the 3D 
macromolecule (PTK, 1skj). The 5-deazaflavins (2a–g) and the computationally designed N-deoxidated 
derivatives, 2-deoxo-2-phenylflavins (4a–j), showed less binding affinity than the N-oxides (3a–j). The higher 
affinity is presumably attributed to the formation of more and/or tighter hydrogen bonds between the C4-oxo of 
flavin-N-oxides and several amino acids at the binding site owing to the increased electronegativity of the oxo at 
the 4-posision due to the N-oxide moiety.  Therefore, the flavin-5-oxides (3a–j) were docked deeply within the 
groove of the binding pocket of PTK forming more hydrogen bonds with Arg 12, Arg 32, Glu 35, and Lys 60. 
Considering the fitting of the 5-deazaflavins (2a–g) and flavin analogs (4a–i) into the PTK binding pocket, it was 
demonstrated that their binding energies were higher in comparison with the flavin-N-oxides (3a–j). Hence, they 
were partially superimposed on the original docked  ur2 ligand 
(4-[3-carboxymethyl-3-(4-phosphonooxybenzyl)ureido]-4-[(3-cyclohexylpropyl)-methylcarbamoyl]butyric acid), 
namely, they are docked slightly away from the groove of the binding site. It is noteworthy that the unsubstituted 
derivatives (2h, 3j and 4j) exhibited especially stronger binding affinities to possess the lower binding free energy 
ca. –8 kcal/mol and also the derivatives (2a, 2i, 2j and 4a ) having a methyl group at the 10-position or a methyl 
or methoxy group on the benzene of the benzopteridine ring showed the binding free energy between –4.99 and 
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–4.18 kcal/mol. It was clarified that the derivatives possessing less binding free energy than –4.2 kcal/mol are 
allowed to fit well into the groove of the binding site. 
 
 
   
The overall good correlation between the growth inhibitory activities (IC50, µM) of the flavin analogs against 
tumor cells and the binding affinities (lower binding free energy) predicted by AutoDock was made clear as 
indicated in Tables 2 and 4. It was found that the stronger binding affinity, the more potent inhibitory activity 
against tumor cells. Especially, the correlation between the binding free energy (ΔGb) and IC50 (µM) values for 
compounds 2a–f and 3a–d against CCRF-HSB-2 and KB tumor cells was fairly good and showed almost same 
correlation coefficients (R2) of 0.64 as shown in Figure 3 and 4. 
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Figure 3. Correlation between the binding free energy (ΔGb) and IC50 (µM) of 2-deoxo-2-phenyl-5-deazaflavins 
(2b, c, e, f) and 2-deoxo-2-phenylflavin-5-oxides (3a–d) against human T-cell acute lymphoblastic leukemia 
(CCRF-HSB-2).  
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Figure 4. Correlation between the binding free energy (ΔGb) and IC50 of 2-deoxo-2-phenyl-5-deazaflavins (2a, b, 
d, f) and 2-deoxo-2-phenylflavin-5-oxides (3a–d) against human oral epithelial carcinoma (KB). 
 
Figure 5 shows the differential docking mode of three flavin analogs. Interestingly, the flavin-5-oxide (3b), whose 
ΔGb was –7.30 kcal/mol, got deeply embedded within the groove of the binding pocket. This is highly correlated 
to its potent inhibition of the proliferation of human T-cell acute lymphoblastic leukemia cells (CCRF-HSB-2, 
IC50 = 0.96 µM). Whereas the 2-deoxo-5-deazaflavin (2b), whose ΔGb and IC50 was –2.50 kcal/mol and 1.79 µM 
against CCRF-SB2, respectively, was docked at the same position as the flavin isomer (4b), whose ΔGb was 
–2.27 kcal/mol. Both flavin (4b) and 5-deazaflavin (2b) appeared to be superimposed onto each other. Moreover, 
the flavin-5-oxide (3b) exhibited three true hydrogen bonds with Arg 12, Arg 32, and Glu 35 of bond angles being 
143.0 o, 175.9 o, and 152.3 o, respectively. Another the false hydrogen bond (1.95 Å) with Cys 42 was omitted 
because of the angle through a hydrogen between C4-O of 3b and N of Cys 42 was 86 o.  While compound 2b 
and 4b didn’t exhibit any hydrogen bond.  As cited in literature,19 the compound with the higher number of 
hydrogen bonds, with the lowest binding energy, and with the smallest RMSD (root mean square deviation) is 
generally said to be a reasonable candidate for potent inhibitors against the enzyme. Actually the docking results 
showed that there was no significant difference between flavins and 2-deoxo-5-deazaflavins with respect to 
docking affinities into the binding site as shown in Table 4 and Figure 5. This may be explained as CH and N are 
equivalent bioisosteres with similar size and comparable electronic properties. 
  
 
Figure 5. The differential docking mode of flavin analogs (2b, 3b and 4b) and the binding pocket shown in 
transparent solid surface with labeled amino acids, and the ur2 ligand is shown as a red line. 
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2.5. Mode of interaction of inhibitors within the binding pocket 
Most docked inhibitors interacted by the same mode of the co-crystallized ur2 ligand within the PTK binding site. 
They exhibited up to three hydrogen bonds involving Arg 32 and Glu 35, which are also involved in ur2 ligand, 
and Arg 12 and Lys 60. Also these inhibitors were involved in a hydrophobic interaction with only three amino 
acids, i.e, Tyr 59, Ile 71 and Asp 92. Therefore, the docked inhibitors exhibited reasonable RMSD values as 
shown in figure 6, where compound 3e was bound, nearly superimposed on the ur2 ligand exhibiting ΔGb being 
–7.44 kcal/mol, three true hydrogen bonds with Arg 12, Arg 32, and Glu 35 of angles being 138.6 o, 173.9 o, 145.8 
o and, respectively and RMSD being 6.94 Å. 
 
 
Figure 6. AutoDock binding affinity of 2-deoxo-9,10-dimethyl-2-phenylflavin-5-oxide (3e) shown as ball and 
stick colored by element. The binding pocket of the pp60c-src shown as solid backbone ribbon with the ur2 ligand 
(blue stick).  
 
Figure 7 illustrates the hydrogen bond and van der Waals contacts similarly to the ur2 ligand with the Src SH2 
domain.  Instead of the binding mode for the phenyl phosphate group of ur2 within the pTyr (pY) pocket, the 
C2-phenyl moiety of 3i assumes the same position but has a different relative orientation, when compared with the 
phosphate of other Src SH2 ligand complexes. The benzene ring of 3i is parallel to the phenyl ring of Tyr 59 
within a distance of 6.65 Å and angle of 94.4o, while the imidazole ring of His 58 is oriented perpendicularly to 
the planar benzopteridine ring within a distance of 3.64 Å and angle of 28.7o. Exceptionally, the same pY pocket 
side chains are involved in the hydrogen-bonding scheme of the C4-Oxo group with Lys 60. Similarly to ur2, Arg 
12 does not make any hydrogen bond with 3i, while Arg 12 does in other structures 3b and 3e discussed 
previously in Figures 5 and 6, respectively. Also 3i interacted hydrophobically with Tyr 59, Ile 71 and Asp 92. 
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Figure 7. Interaction of compound 3i (ball and stick, colored by element,) docked into the binding pocket of PTK 
whose amino acids are shown as labeled lines. 
 
3. Conclusion 
 
In this study, ten 2-deoxo-5-deazaflavins (2a–j) and nine flavin-5-oxides (3a–i) were synthesized to investigate 
their biological activities. In vitro growth inhibitory activities of compounds 2a–j and 3a–i against NCI-H 460, 
HCT 116, A 431, CCRF-HSB-2 and KB cells showed significant potential antitumor activities. Interestingly, the 
activities of some compounds 2a, 2c, 3a and 3f against HCT 116 cells were higher than that of cisplatin. 
Especially, compound 3f (IC50: 0.72 µM) exhibited 3 fold more potent antitumor activity than that of cisplatin 
(IC50: 2.33 µM). Approximately similar inhibitory activities (IC50: 0.5–2.0 µM) to Ara-C (IC50: 0.15 µM) against 
CCRF-HSB-2 cells were observed in many compounds. Additional results of promising antitumor activity were 
obtained in compounds showing potential activities of 0.5–5.0 µM (IC50) against KB cells. Furthermore, in vivo 
antitumor activity of 2-deoxo-10-methyl-2-phenyl-5-deazaflavin (2a) against human adenocarcinoma A 431 cells 
implanted subcutaneously into mice was undertaken. As the result, the tumor volume was reduced to 57.2% after 
17 days of the intratumoral administration (25 mg/kg), to 53.4% after 10 days of the intraperitoneal administration 
(100 mg/kg) and to 51.8% after 18 days of the oral administration (150 mg/kg).  
The AutoDock study of 2-deoxo-2-phenyl-5-deazaflavins (2a–j), 2-deoxo-2-phenylflavin-5-oxides (3a–j), and 
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2-deoxo-2-phenylflavins (4a–j) was carried out, and they were docked within the protein tyrosine kinase (PTK 
pp60c-src, PDB code: 1skj). All flavin-5-oxides (3a–j) exhibited the lowest binding free energies between –7.84 
and –5.95 kcal/mol. Namely, they possessed the highest potential binding affinity into the target site. The 
correlation between the binding free energy (ΔGb, kcal/mol) and IC50 (µM) values against CCRF-HSB-2 and KB 
tumor cells showed fairly good the correlation coefficients. 2-Deoxo-10-ethyl-2-phenylflavin-5-oxide (3b), whose 
ΔGb was –7.30 kcal/mol, got deeply embedded within the groove of the binding pocket, and is highly correlated to 
its potent inhibition of the proliferation of human T-cell acute lymphoblastic leukemia cells (CCRF-HSB-2, IC50 
= 0.96 µM).  
Thus, SAR studies by computational design, chemical synthesis and biological investigation revealed new 
structural requirements for the modified flavins that would enhance the binding characteristics within the protein 
tyrosine kinase. The most effective molecules for flavin and 5-deazaflavins as antitumor activities were elucidated 
that a phenyl substituent at the 2-position is necessary.  
 
4. Experimental 
4.1. Chemistry 
Mps were obtained on a Yanagimoto micro melting point apparatus and were uncorrected. Microanalyses were 
measured by Yanaco CHN Corder MT-5 apparatus. IR spectra were recorded on a JASCO FT/IR-200 
spectrophotometer as Nujol mulls. 1H and 13C NMR spectra were obtained using a Varian VXR 300 MHz and 75 
MHz spectrophotometer, respectively, and chemical shift values were expressed in δ values (ppm) relative to 
tetramethylsilane (TMS) as internal standard. Coupling constants are given in Hz. UV spectra were measured in 
absolute EtOH using Hitachi U-2001 and Beckman DU-68S UV spectrophotometers and absorption values in 
italic refers to wave lengths at which shoulders or inflexions occur in the absorption. All reagents were of 
commercial quality and were used without further purification. Organic solvents were dried in the presence of an 
appropriate drying agent and were stored over suitable molecular sieves. Reaction progress was monitored by 
analytical thin layer chromatography (TLC) on pre-coated glass plates (silica gel 60F254-plate-Merck) and the 
products were visualized by UV light.    
 
4.1.1. General procedure for the preparation of 6-(N-alkylanilino)-2-phenylpyrimidin-4(3H)-ones (1a-j).  
A mixture of 6-chloro-2-phenylpyrimidin-4(3H)-one13 (3.5 g, 17 mmol) and N-alkylaniline (0.051–0.085 mol) 
was heated under nitrogen atmosphere at 180–200 °C for 0.5–5 h. After cooling, the resulting solid was crushed 
with diethyl ether to get powdery crystals, which were filtered off, washed with water, dried and recrystallized 
from an appropriate solvent with charcoal to afford colorless needles. 
 
4.1.1.1. 6-(N-Methylanilino)-2-phenylpyrimidin-4(3H)-one (1a).13  Yield, 4.47 g (95%); mp 248 °C (EtOH) 
(Lit.12 mp 248 °C); 1H NMR (CDCl3), δ 3.56 (3 H, s, 6-NMe), 5.27 (1 H, s, 5-H), 7.28–7.33 (3 H, m, N-Ph-o,pH), 
7.42–7.54 (5 H, m, N-Ph-mH, 2-Ph-m,pH), 8.17–8.21 (2 H, m, 2-Ph-oH ), 12.60 (1 H, br s, 3-NH);  IR (cm-1) 
3240 (NH), 1650 (C=O). 
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4.1.1.2. 6-(N-Ethylanilino)-2-phenylpyrimidin-4(3H)-one (1b).13  Yield, 4.01 g (81%); mp 268 °C (Lit.13 mp 
265 °C); 1H NMR (CDCl3), δ 1.27 (3 H, t, J = 7.2 Hz, 6-NCH2-CH3 ), 4.06 (2 H, q, J = 7.2 Hz, 6-NCH2-CH3), 
5.10 (1 H, s, 5-H), 7.24–7.27 (2 H, m, N-Ph-oH ), 7.31–7.37 (1 H, m, N-Ph-pH ), 7.42–7.45 (1 H, m, N-Ph-mH ), 
7.48–7.50 (3 H, m, 2-Ph-m,pH ), 8.16–8.19 (2 H, m, 2-Ph-oH ), 12.37 (1 H, br s, 3-NH); IR (cm-1) 3210 (NH), 
1635 (C=O). 
 
4.1.1.3. 6-(N-Isopropylanilino)-2-phenylpyrimidin-4(3H)-one (1c).  Yield, 2.12 g (41%); mp > 300 °C 
(MeOH); 1H NMR (CDCl3), δ 1.18 (6 H, d, J = 6.6 Hz, 6-N-CH-(CH3)2, 4.78 (1 H, s, 5-H), 5.40 (1 H, quintet, J = 
6.6 Hz, 6-N-CH-(CH3)2), 7.13–7.18 (2 H, m, N-Ph-oH), 7.36–7.54 (6 H, m, 2-Ph-m,pH and N-Ph-m,pH), 
8.10–8.14 (2 H, m, 2-Ph-oH ), 11.59 (1 H, br s, 3-NH); IR (cm-1) 3200 (NH), 1635 (C=O); Anal. C19H19N3O 
requires C, 74.73; H, 6.27; N, 13.76; Found C, 74.69; H, 6.39; N, 13.60. 
 
4.1.1.4. 6-(N-Methyl-4-methylanilino)-2-phenylpyrimidin-4(3H)-one (1d).  Yield, 4.75 g (96%); mp 
265–267 °C (dioxane); 1H NMR (CDCl3), δ 2.40 (3 H, s, pMe), 3.54 (3 H, s, 6-NMe), 5.23 (1 H, s, 5-H ), 7.16 (2 
H, dd, J2”,3” = 9.0 Hz, J3”,5” = 2.1 Hz, N-Ar-oH), 7.24 (2 H, dd, J2”,3”  = 8.7 Hz, J2”,6” = 2.1 Hz, N-Ar-mH), 
7.47–7.52 (3 H, m, 2-Ph-m,pH), 8.16–8.20 (2 H, m, 2-Ph-oH), 12.49 (1 H, br s, 3-NH); IR (cm-1) 3210 (NH), 
1630 (C=O); Anal. C18H17N3O requires C, 74.20; H, 5.88; N, 14.42; Found C, 74.00; H, 5.91; N, 14.36. 
 
4.1.1.5. 6-(N-Methyl-2-methylanilino)-2-phenylpyrimidin-4(3H)-one (1e).  Yield, 3.07 g (62%); mp 
254–256 °C (EtOH–H2O);  1H NMR (CDCl3), δ 2.20 (3H, s, oMe), 3.51 (3 H, s, 6-NMe), 4.84 (1 H, s, 5-H), 
7.15–7.21 (1 H, m, N-Ar-oH), 7.27–7.45 (3 H, m, N-Ar-m,pH ), 7.46–7.54 (3 H, m, 2-Ph-m,pH ), 8.15–8.30 (2 H, 
m, 2-Ph-oH ), 12.36 (1 H, br s, 3NH); IR (cm-1) 3210 (NH), 1640 (C=O); Anal. C18H17N3O requires C, 74.20; H, 
5.88; N, 14.42; Found C, 73.83; H, 5.94; N, 14.42. 
 
4.1.1.6. 6-(N-Methyl-4-methoxyanilino)-2-phenylpyrimidin-4(3H)-one (1f).  Yield, 4.86 g (93%); mp 
273–275 °C (EtOH); 1H NMR (CDCl3), δ 3.52 (3 H, s, 6-NMe), 3.85 (3 H, s, OMe), 5.18 (1 H, s, 5-H), 6.96 (2 H, 
dd, J2”,3” = 9.0 Hz, J3”,5” = 2.1 Hz, N-Ar-oH), 7.19 (2 H, d, J2”,3” = 9.0 Hz, J2”,6” = 2.1 Hz,, N-Ar-mH ), 7.46–7.52 (3 
H, m, 2-Ph-m,pH ), 8.15–8.20 (2 H, m, 2-Ph-oH ), 12.29 (1 H, br s, 3-NH); IR (cm-1) 3210 (NH), 1630 (C=O); 
Anal. C18H17N3O2 requires C, 70.34; H, 5.58; N, 13.67; Found C, 70.10; H, 5.66; N, 13.28. 
 
4.1.1.7. 6-(N-Methyl-3-methoxyanilino)-2-phenylpyrimidin-4(3H)-one (1g).  Yield, 3.87 g (74%); mp 
235–237 °C (EtOH); 1H NMR (CDCl3), δ 3.55 (3 H, s, 6-NMe), 3.83 (3 H, s, OMe), 5.29 (1 H, s, 5-H), 6.82–6.90 
(3 H, m, N-Ar-o,pH ), 7.32–7.38 (1 H, m, N-Ar-mH ), 7.48–7.54 (3 H, m, 2-Ph-m,pH ), 8.14–8.19 (2 H, m, 
2-Ph-oH ), 12.18 (1 H, br s, 3-NH); IR (cm-1) 3200 (NH), 1645 (C=O); Anal. C18H17N3O2 requires C, 70.34; H, 
5.58; N, 13.67; Found C, 70.09; H, 5.69; N, 13.62. 
 
4.1.1.8. 6-(N-Ethyl-4-methylanilino)-2-phenylpyrimidin-4(3H)-one (1h).  Yield, 4.77 g (92%); mp 
295–297 °C (decompo., EtOH); 1H NMR (CDCl3), δ 1.25 (3 H, t, J = 7.0 Hz, 6-NCH2-CH3 ), 2.40 (3 H, s, pMe), 
4.04 (2 H, q, J = 7.0 Hz, 6-NCH2-CH3), 5.07 (1 H, s, 5-H), 7.11 (2 H, br d, J = 8.4 Hz, N-Ar-oH ), 7.24 (2 H, br d, 
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J = 8.4 Hz, N-Ar-mH ), 7.48–7.54 (3 H, m, 2-Ph-m,pH ), 8.15–8.19 (2 H, m, 2-Ph-oH ), 12.25 (1 H, br s, 3-NH); 
IR (cm-1) 3200 (NH), 1635 (C=O); Anal. C19H19N3O requires C, 74.73; H, 6.27; N, 13.76; Found C, 74.66; H, 
6.36; N, 13.94. 
 
4.1.1.9. 6-(N-Ethyl-2-methylanilino)-2-phenylpyrimidin-4(3H)-one (1i).  Yield, 3.01 g (58%); mp 249–251 °C 
(EtOH); 1H NMR (CDCl3), δ 1.25 (3 H, t, J = 7.2 Hz, 6-NCH2-CH3 ), 2.19 (3 H, s, oMe), 4.27 (2 H, br s, 
6-NCH2-CH3), 4.80 (1 H, s, 5-H), 7.13–719 (2 H, m, N-Ar-3” and 6”H ), 7.28–7.34 (2 H, m, N-Ar-4” and 5”-H), 
7.46–7.54 (3 H, m, 2-Ph-m, pH ), 8.16–8.22 (2 H, m, 2-Ph-oH ), 11.91 (1 H, br s, 3-NH); IR (cm-1) 3200 (NH), 
1640 (C=O); Anal. C19H19N3O . 1/10 H2O requires C, 74.29; H, 6.30; N, 13.68; Found C, 74.13; H, 6.33; N, 13.46. 
 
4.1.1.10. 6-(N-Methyl-3,4,5-trimethoxyanilino)-2-phenylpyrimidin-4(3H)-one (1j).  Yield, 5.93 g (95%); mp 
294 °C (decompo., EtOH); 1H NMR (CDCl3), δ 3.55 (3 H, s, 6-NMe), 3.85 (6 H, s, N-Ar-3”,5”-diOMe), 3.89 (3 
H, s, N-Ar-4”-OMe), 5.23 (1 H, s, 5-H), 6.50 (2 H, s, N-Ar-2”H and 6”H), 7.45–7.60 (3 H, m, 2-Ph-m,pH), 
8.17–8.24 (2 H, m, 2-Ph-oH), 12.54 (1 H, br s, 3-NH) ; IR (cm-1) 3210 (NH), 1635 (C=O); Anal. C20H21N3O4 
requires C, 65.38; H, 5.76; N, 11.44; Found C, 64.98; H, 5.79; N, 11.06. 
 
4.1.2. General procedure for the preparation of 2-deoxo-2-phenyl-5-deazaflavin derivatives (2a-j).  
A mixture of 6-(N-alkylanilino)- or 6-anilino-2-phenylpyrimidin-4(3H)-ones15 (1, 0.05 mol) and phosphoryl 
chloride (77 g, 0.5 mol) in N,N-dimethylformamide (100 mL) was heated under stirring at 90 °C for 1–4 h. Then, 
the reaction mixture was poured onto ice and neutralized with aqueous ammonia (pH 7). The yellow crystals, 
which separated, were filtered off, washed with water, dried and recrystallized from an appropriate solvent. All 
compounds were obtained as yellow (2a–g) or pale yellow needles (2h–j). 
 
4.1.2.1. 10-Methyl-2-phenylpyrimido[4,5-b]quinolin-4(10H)-one (2a).13  Yield, 13.5 g (94%); mp 293–295 °C 
(EtOH) (Lit.12 mp 290 °C); 1H NMR (CDCl3), δ 4.45 (3 H, s, 10-Me), 7.34–7.49 (3 H, m, 6-, 7-, and 9-H), 
7.54–7.61 (1 H, m, 8-H), 7.84–7.89 (1 H, m, Ph-pH ), 7.95–8.01 (2 H, m, Ph-mH), 8.53–8.59 (2 H, m, Ph-oH), 
9.27 (1 H, s, 5-H); IR (cm-1) 1645 (C=O). 
 
4.1.2.2. 10-Ethyl-2-phenylpyrimido[4,5-b]quinolin-4(10H)-one (2b).13  Yield, 12.21 g (81%); mp > 300 °C 
(decompo., EtOH) (Lit.13 mp 303 °C); 1H NMR (CDCl3), δ 1.64 (3 H, t, J = 7.2 Hz, 10-CH2-CH3 ), 5.16 (2 H, q, J 
= 7.2 Hz, 10-CH2-CH3), 7.42–7.54 (3 H, m, 6-, 7-, and 9-H), 7.57–7.65 (1 H, m, 8-H), 7.87–7.92 (1 H, m, Ph-pH), 
7.96–8.07 (2 H, m, Ph-mH ), 8.63–8.68 (2 H, m, Ph-oH), 9.34 (1 H, s, 5-H);  IR (cm-1) 1640 (C=O). 
 
4.1.2.3. 7,10-Dimethyl-2-phenylpyrimido[4,5-b]quinolin-4(10H)-one (2c).  Yield, 10.25 g (68%); mp 
295–297 °C (decompo., DMF); 1H NMR [(CD3)3SO], δ 2.44 (3 H, s, 7-Me), 4.46 (3 H, s, 10-Me), 7.43–7.66 (3 H, 
m, 6-, 8-, and 9-H), 7.88–8.22 (3 H, m, Ph-m,pH ), 8.43–8.61 (2 H, m, Ph-oH), 9.29 (1 H, s, 5-H); IR (cm-1) 1650 
(C=O); Anal. C19H15N3O requires C, 75.73; H, 5.02; N, 13.94; Found C, 75.31; H, 5.18; N, 13.57. 
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4.1.2.4. 9,10-Dimethyl-2-phenylpyrimido[4,5-b]quinolin-4(10H)-one (2d).  Yield, 9.19 g (61%); mp 
262–264 °C (DMF); 1H NMR [(CD3)3SO], δ 2.98 (3H,s, 9-Me), 4.57 (3 H, s, 10-Me), 7.53–7.61 (4 H, m, 7-H and 
Ph-m,pH), 7.92 (1 H, br d, J7,8 = 7.8 Hz, 8-H), 8.23 (1 H, d, J 6,7 = 7.8 Hz , Ph-6H), 8.49–8.54 (2 H, m, Ph-oH ), 
9.36 (1 H, s, 5-H); IR (cm-1) 1640 (C=O); Anal. C19H15N3O . 1/5 H2O requires C, 74.83; H, 5.09; N, 13.78; Found 
C, 74.80; H, 5.21; N, 13.74. 
 
4.1.2.5. 7-Methoxy-10-methyl-2-phenylpyrimido[4,5-b]quinolin-4(10H)-one (2e).  Yield, 15.08 g (95%); mp 
279–281 °C (decompo., DMF); 1H NMR [(CD3)3SO], δ 3.95 (3 H , s, 7-OMe), 4.51 (3 H, s, 10-Me), 7.50–7.60 (3 
H, m, Ph-m,pH), 7.78 (1 H, dd, J6,8 = 2.4 Hz, J8,9 = 9.0 Hz, 6-H), 7.92 (1 H, d, J6,8 = 2.4 Hz, 8-H ), 8.20 (1 H, d, 
J8,9 = 9.0 Hz, 9-H ), 8.52–8.57 (2 H, m, Ph-oH ), 9.36 (1 H, s, 5-H); IR (cm-1) 1620 (C=O); Anal. C19H15N3O2 . 
1/10 H2O requires C, 71.51; H, 4.80; N, 13.17; Found C, 71.27; H, 4.97; N, 13.42. 
 
4.1.2.6. 8-Methoxy-10-methyl-2-phenylpyrimido[4,5-b]quinolin-4(10H)-one (2f).  Yield, 14.60 g (92%); mp 
265–267 °C (decompo., EtOH); 1H NMR [(CD3)3SO], δ 4.10 (3 H, s, 8-OMe), 4.45 (3 H, s, 10-Me), 7.35 (1 H, dd, 
J6,7 = 9.0 Hz, J7,9 = 2.1 Hz, 7-H), 7.44 (1 H, d, J7,9 = 2.1 Hz, 9-H ), 7.25–7.62 (3 H, m, Ph-m,pH), 8.31 (1 H, d, J6,7 
= 9.0 Hz, 6-H), 8.50–8.58 (2 H, m, Ph-oH ), 9.31 (1 H, s, 5-H); IR (cm-1) 1625 (C=O); Anal. C19H15N3O2 . 3/10 
H2O requires C, 70.71; H, 4.87; N, 13.02; Found C, 70.30; H, 4.89; N, 12.88. 
 
4.1.2.7. 10-Ethyl-7-methyl-2-phenylpyrimido[4,5-b]quinolin-4(10H)-one (2g).  Yield, 11.8 g (75%); mp 
291–293 °C (decompo., DMF); 1H NMR [(CD3)3SO], δ 1.51 (3 H, t, J = 7.0 Hz, 10-CH2-CH3 ), 2.54 (3 H, s, 
7-Me), 5.18 (2 H, q, J = 7.0 Hz, 10-CH2-CH3), 7.50–7.60 (3 H, m, 6-H, 8-H, and Ph-pH ), 7.98 (1 H, d, J8,9 = 9.3 
Hz, 9-H), 8.17–8.23 (2 H, m, Ph-mH), 8.50–8.58 (2H, m, Ph-oH ), 9.33 (1 H, s, 5-H); IR (cm-1) 1640 (C=O); Anal. 
C20H17N3O requires C, 76.17; H, 5.43; N, 13.32; Found C, 75.82; H, 5.65; N, 13.22. 
 
 
4.1.2.8. 2-Phenylpyrimido[4,5-b]quinolin-4(10H)-one (2h).  Yield, 11.75 g (86%); mp > 300 °C (DMF); 1H 
NMR [(CD3)3SO], δ 7.5–7.76 (4 H, m, 6-H,7-H, and Ph-mH), 7.94 (1 H, ddd, J6,8 = 1.5 Hz, J7,8 = 8.7 Hz, J8,9 = 
8.7 Hz, 8-H ), 8.09 (1 H, dd, J7,9 = 1.5 Hz, J8,9 = 8.7 Hz, 9-H ), 8.24–8.32 (3 H, m, Ph-o,pH ), 9.30 (1 H, s, 5-H), 
12.64 (1 H, br s, 10-NH ); IR (cm-1) 3170 (NH), 1680 (C=O); Anal. C17H11N3O requires C, 74.71; H, 4.06; N, 
15.38; Found C, 74.36; H, 4.31; N, 15.24. 
 
4.1.2.9. 9-Methyl-2-phenylpyrimido[4,5-b]quinolin-4(10H)-one (2i).  Yield, 9.77 g (68%); mp > 300 °C 
(DMF); 1H NMR [(CD3)3SO], δ 2.78 (3 H, s, 9-Me), 7.45–7.70 (4 H, m, 6-H, 7-H, and Ph-mH), 7.75–7.82 (1 H, 
m, 8-H ), 8.10–8.19 (1 H, m, Ph-pH), 8.25–8.30 (2 H, m, Ph-oH ), 9.24 (1 H, s, 5-H), 12.63 (1H, br s, 10-NH ); IR 
(cm-1) 3160 (NH), 1670 (C=O); Anal. C18H13N3O requires C, 75.25; H, 4.56; N, 14.63; Found C, 74.85; H, 4.82; 
N, 14.78. 
 
4.1.2.10. 8-Methoxy-2-phenylpyrimido[4,5-b]quinolin-4(10H)-one (2j).  Yield, 11.68 g (77%); mp > 300 °C 
(DMF); 1H NMR [(CD3)3SO], δ 3.99 (3 H, s, 8-OMe), 7.31 (1 H, dd, J6,7 = 7.5 Hz, J7,9 = 2.1 Hz, 7-H), 7.42 (1 H, 
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d, J7,9 = 2.1 Hz, 9-H), 7.55–7.72 (3 H, m, Ph-m,pH), 8.14 (1 H, d, J = 7.8 Hz, 6-H), 8.24–8.29 (1 H, m, Ph-oH), 
9.16 (1H, s 5-H), 12.57 (1 H, br s, 10-NH ); IR (cm-1) 3160 (NH), 1680 (C=O); Anal. C18H13N3O2 . 1/10 H2O 
requires C, 71.28; H, 4.32; N, 13.85; Found C, 71.11; H, 4.54; N, 13.54. 
 
4.1.3. Methylation of 2-phenylpyrimido[4,5-b]quinolin-4(10H)-one (2h). A mixture of 
2-phenylpyrimido[4,5-b]quinolin-4(10H)-one (2h, 0.5 g, 1.83 mmol), methyl iodide (1.30 g, 9.16 mmol) and 
anhydrous potassium carbonate (1.01 g, 7.31 mmol) in DMF (50 mL) was stirred at room temperature for 10 h. 
After the reaction was complete, the precipitated potassium carbonate was filtered off. The residue obtained by 
concentration in vacuo was subjected to column chromatography on silica gel using a mixture of n-hexane and 
ethyl acetate (1:1) as eluting solvent to isolate the corresponding 
10-methyl-2-phenylpyrimido[4,5-b]quinolin-4(10H)-one (2a, 0.425 g , 80%), which was identical to the product 
(2a) prepared by the reaction of 1a with Vilsmeier reagent in all spectral data as described above.  
 
4.1.4. General procedure for the preparation of 2-deoxo-2-phenylflavin-5-oxide derivatives (3a-i).  
To a stirring solution of 6-(N-alkylanilino)-2-phenylpyrimidin-4(3H)-ones (1, 10 mmol) in acetic acid (5–15 mL) 
at 10–15 °C was added sodium nitrite (20–40 mmol) by portions, and the mixture was stirred for 2–5 h at room 
temperature. The solid deposited was collected by suction filtration and washed with water. Then, the solid dried 
was recrystallized from an appropriate solvent. All compounds were obtained as red needles.  
 
4.1.4.1. 4,10-Dihydro-10-methyl-4-oxo-2-phenylbenzo[g]pteridine-5-oxide (3a).  Yield, 2.19 g (72%); mp > 
300 °C (DMF); 1H NMR [(CD3)3SO], δ 4.29 (3 H, s, 10-Me), 7.50–7.60 (3 H, m, Ph-m,pH), 7.73 (1 H, ddd, J6,7 = 
7.8 Hz, J7,8 = 7.8 Hz, J7,9 = 1.5 Hz, 7-H), 8.09 (1 H, ddd, J6,8 = 1.5 Hz, J7,8 = 7.8 Hz, J8,9 = 7.8 Hz, 8-H ), 8.21 (1 H, 
dd, J7,9 = 1.5 Hz, J8,9 = 7.8 Hz, 9-H ), 8.45 (1 H, dd, J6,7 = 8.7 Hz, J6,8 = 1.5Hz, 6-H), 8.47–8.51 (2 H, m, Ph-oH ); 
IR (cm-1), 1540 (N-O), 1650 (C=O); Anal. C17H12N4O2 requires C, 67.10; H, 3.97; N, 18.41; Found C, 67.11; H, 
4.20; N, 18.62. 
                                                                  
4.1.4.2 10-Ethyl-4,10-dihydro-4-oxo-2-phenylbenzo[g]pteridine-5-oxide (3b).  Yield, 2.42 g (76%); mp 
262–264 °C (decompo., EtOH); 1H NMR [(CD3)3SO], δ 1.52 (3 H, t, J = 6.9 Hz, 10-CH2-CH3), 4.98 (2 H, q, J = 
6.9 Hz, 10-CH2-CH3), 7.49–7.61 (3 H, m, Ph-m,pH), 7.72 (1 H, ddd, J6,7 = 7.8 Hz, J7,8 = 7.8 Hz, J7,9 = 1.5 Hz, 
7-H), 8.07 (1 H, ddd, J6,8 = 1.5 Hz, J7,8 = 7.8 Hz, J8,9 = 7.8 Hz, 8H), 8.23 (1 H, dd, J7,9 = 1.5 Hz, J8,9 = 7.8 Hz, 
9-H ), 8.44–8.50 (2 H, m, Ph-oH), 8.56 (1 H, dd, J6,7 = 7.8 Hz, J6,8 = 1.5 Hz, 6-H); IR (cm-1), 1540 (N-O), 1640 
(C=O); Anal. C18H14N4O2 requires C, 67.91; H, 4.43; N, 17.60; Found C, 67.94; H, 4.62; N, 17.58. 
 
4.1.4.3. 4,10-Dihydro-10-isopropyl-4-oxo-2-phenylbenzo[g]pteridine-5-oxide (3c).  Yield, 2.66 g (80%); mp 
267–269 °C (MeOH); 1H NMR [(CD3)3SO], δ 1.85 (6 H, d, J = 6.9 Hz, 10-CH-(CH3)2), 6.19 (1 H, br s, 10-CH 
(CH3)2), 7.56–7.64 (3 H, m, Ph-m,pH), 7.71 (1 H, ddd, J6,7 = 7.8 Hz, J7,8 = 7.8 Hz, J7,9 = 1.5 Hz, 7-H), 8.04 (1 H, 
ddd, J6,8 = 1.5 Hz, J7,8 = 7.8 Hz, J8,9 = 7.8 Hz, 8-H), 8.37 (1 H, dd, J7,9 = 1.5 Hz, J8,9 = 7.8 Hz, 9-H ), 8.44–8.50 (3 
H, m, 6, Ph-oH ); IR (cm-1), 1540 (N-O), 1640 (C=O); Anal. C19H16N4O2 requires C, 68.66; H, 4.85; N, 16.86; 
Found C, 68.45; H, 4.94; N, 16.69. 
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4.1.4.4. 4,10-Dihydro-7,10-dimethyl-4-oxo-2-phenylbenzo[g]pteridine-5-oxide (3d).  Yield, 2.16 g (68%); mp 
> 300 °C (decompo., DMF); 1H NMR [(CD3)3SO], δ 2.51 (3 H, s, 7-Me), 4.27 (3 H, s, 10-Me), 7.49-7.61 (3 H, m, 
Ph-m,pH), 7.92 (1 H, dd, J6,8 = 1.5 Hz, J8,9 = 8.7 Hz, 8-H), 8.12 (1 H, d, J8,9 = 8.7 Hz, 9-H), 8.25 (1 H, d, J6,8 = 1.5 
Hz, 6-H), 8.45–8.48 (2 H, m, Ph-oH ); IR (cm-1), 1540 (N-O), 1640 (C=O); Anal. C18H14N4O2 requires C, 67.91; 
H, 4.43; N, 17.60; Found C, 68.12; H, 4.56; N, 17.51. 
 
4.1.4.5. 4,10-Dihydro-9,10-dimethyl-4-oxo-2-phenylbenzo[g]pteridine-5-oxide (3e).  Yield, 2.61 g (82%); mp 
> 300 °C (DMF); 1H NMR [(CD3)3SO], δ 1.91 (3 H, s, 9-Me), 4.52 (3 H , s, 10-Me), 7.63–7.84 (4 H, m, 7-H and 
Ph-m,pH), 8.08 (1 H, dd, J6,8 = 1.5 Hz, J7,8 = 7.5 Hz, 8-H), 8.41–8.48 (3 H, m, 6-H and Ph-oH); IR (cm-1), 1540 
(N-O), 1655 (C=O); Anal. C18H14N4O2 requires C, 67.91; H, 4.43; N, 17.60; Found C, 68.16; H, 4.68; N, 17.63. 
 
4.1.4.6. 4,10-Dihydro-7-methoxy-10-methyl-4-oxo-2-phenylbenzo[g]pteridine-5-oxide (3f).  Yield, 2.67 g 
(80%); mp > 300 °C (DMF); 1H NMR [(CD3)3SO], δ 4.07 (3 H, s, 7-OMe), 4.55 (3 H, s, 10-Me), 7.65–7.73 (2 H, 
m, Ph-mH), 7.75–7.80 (1 H, m, Ph-pH), 7.92 (1 H, d, J6,8 = 1.5 Hz, 6-H), 8.01 (1 H, d, J = 9.0 Hz, 9-H), 8.41–8.47 
(2 H, m, Ph-oH ), 8.50 (1 H, dd, J6,8 = 1.5 Hz, J8,9 = 9.0 Hz, 8-H); IR (cm-1), 1539 (N-O), 1645 (C=O); Anal. 
C18H14N4O3 requires C, 64.66; H, 4.22; N, 16.76; Found C, 64.69; H, 4.47; N, 16.85. 
 
4.1.4.7. 4,10-Dihydro-8-methoxy-10-methyl-4-oxo-2-phenylbenzo[g]pteridine-5-oxide (3g).  Yield, 2.71 g 
(81%); mp > 300 °C (DMF); 1H NMR [(CD3)3SO], δ 4.17 (3 H, s, 8-OMe), 4.48 (3 H, s, 10-Me), 7.57–7.70 (4 H, 
m, 9-H and Ph-m,pH ), 7.77 (1 H, d, J6,7 = 7.5 Hz, 6-H), 8.42–8.47 (2 H, m, Ph-oH ), 8.52 (1 H, dd, J6,7 = 8.7 Hz, 
J7,9 = 1.5 Hz, 7-H); IR (cm-1), 1540 (N-O), 1640 (C=O); Anal. C18H14N4O3 requires C, 64.66; H, 4.22; N, 16.76; 
Found C, 64.68; H, 4.56; N, 16.82. 
 
4.1.4.8. 10-Ethyl-4,10-dihydro-7-methyl-4-oxo-2-phenylbenzo[g]pteridine-5-oxide (3h).  Yield, 2.56 g (77%); 
mp 268–269 °C (MeOH); 1H NMR [(CD3)3SO], δ 1.48 (3 H, t, J = 7.2 Hz, 10-CH2-CH3), 2.49 (3 H, s, 7-Me), 
4.97 (2 H, q, J = 7.2 Hz, 10-CH2-CH3), 7.51–7.59 (3 H, m, Ph-m,pH), 7.92 (1 H, dd, J6,8 = 9.0 Hz, J8,9 = 1.5 Hz, 
8-H), 8.17 (1 H, d, J = 9.0 Hz , 9-H), 8.28 (1 H, d, J6,8 = 1.5 Hz, 6-H), 8.44–8.49 (2 H, m, Ph-oH ); IR (cm-1), 
1540 (N-O), 1650 (C=O); Anal. C19H16N4O2 requires C, 68.66; H, 4.85; N, 16.86; Found C, 68.54; H, 4.96; N, 
16.78. 
 
4.1.4.9. 4,10-Dihydro-6,7,8-trimethoxy-10-methyl-4-oxo-2-phenylbenzo[g]pteridine-5-oxide (3i).  Yield, 3.19 
g (81%); mp > 300 °C (DMF); 1H NMR [(CD3)3SO], δ 3.94 (3 H, s, 7-OMe), 4.18 (3 H, s, 8-OMe), 4.21 (3 H, s, 
6-OMe), 4.43 (3 H, s, 10-Me), 7.25 (1 H, s, 9-H), 7.45–7.60 (3 H, m, Ph-m,pH), 8.53–8.56 (2 H, m, Ph-oH); IR 
(cm-1), 1550 (N-O), 1645 (C=O); Anal. C20H18N4O5 . 7/10 H2O requires C, 59.02; H, 4.80; N, 13.77; Found C, 
59.15; H, 4.67; N, 13.40. 
 
4.2. Growth inhibitory activities of 2-deoxo-2-phenyl-5-deazaflavins (2) and 
2-deoxo-2-phenylflavin-5-oxides (3) against human tumor cell lines 
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AraC was a commercial product of Yamasa Corporation (Choshi, Japan) and 
3-(3,4-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) was purchased from Sigma (St. Louis, MO). 
Five human tumor cell lines of NCI-H 460 (human lung cancer), HCT 116 (human colon carcinoma), A 431 
(human adenocarcinoma), CCRF-HSB-2 (human T-cell acute lymphoblastoid leukemia), and KB (human oral 
epidermoid carcinoma) were used in this study. Cell lines were maintained in RPMI 1640 medium (Life 
Technologies, Rockville, MD) supplemented with 10% heat-inactivated fetal bovine serum (Moregate 
Laboratories, Melbourne, Australia) and 60 µg/mL of kanamycin.  
The MTT assay developed by Mosmann20 was modified21 and used to determine the inhibitory effects of test 
compounds on cell growth in vitro. Briefly, medium containing 5 x 103 cells (NCI-H 460, HCT 116, A 431, 
CCRF-HSB-2 or KB cells) was seeded into each well of a 96-well microplate, with the compound solution added 
simultaneously to triplicate wells, before the final volume was made up to 100 µL. The plate was incubated at 
37 °C for 72 h in a humidified atmosphere of 5% CO2. After the incubation, 10 µL of an MTT solution (5 mg/mL 
in phosphate buffered saline lacking calcium and magnesium) was added to each well. After a further incubation 
for 4 h at 37 °C, 100 µL of 0.02 N HCl/ 50% N,N-dimethylformamide/ 20% SDS was added to solubilize any 
MTT-formazan that had formed. The optical density of each well was measured at 570 nm (OD570) with a 
microplate reader and the inhibition of cell growth (%) was calculated as (1 – T/C) x 100, where C is the mean 
OD570 of the control group and T is that of the treated group. The IC50 was determined from the dose-response 
curve. 
 
4.3. In vivo antitumor activities of 2-deoxo-2-phenyl-5-deazaflavins (2a and 2b)   
Antitumor activity of 2-deoxo-2-phenyl-5-deazaflavins (2a, b) against subcutaneously transplanted human 
adenocarcinoma A 431 was tested according to the modified method developed by Inaba et al.22  The A 431 
human adenocarcinoma was subcutaneously transplanted into mice skin of neonate (BALB/c nude mice), and the 
administration of test compounds was started on the day (day 1) when the mice show tumor growth in the 100-
–300 mm3 range. Staurosporine as a positive control was used at 1mg/kg and compounds 2a, b was used at 25 
mg/kg for intratumoral administration (i.t.), at 100 mg/kg for intra-abdominal administration (i.p.), and at 75 and 
150 mg/kg for oral administration (p.o.). Since the test compounds showed poor solubility in water, the 
administrations of them suspended in 0.5% gum arabic were done into intra-tumor (i.t.), intraperitoneally (i.p.) or 
orally (p.o.). The administration schedule for i.t. was 5 consecutive daily injections per week for 3 weeks (days 1-
–5, 8–12, and 15–19). Administration schedules for i.p. and p.o. were consecutive daily administration for 10 days 
(days 1–10). The tumor volume (T/C %) was measured on the 17 days (i.t.), 10 days (i.p.) and 18 days (p.o.) after 
the treatment of chemicals. The length (a) and width (b) of the tumor mass were measured twice or 3 times a week, 
and the tumor volume was calculated according to the following formula: tumor volume (mm3) = (a x b2)/2. 
Relative tumor volume (T/C %) was calculated by the Battele Columbus formula, T/C % = (Tn/T1) x 100/(Cn/C1), 
in which Cn = Tumor volume of control animals on day n, and Tn = Tumor volume of actively treated animals on 
day n of the treatment.  
 
4.4. Docking study 
AutoDock 3.05,18 a grid-based docking program, was used for docking study. The crystal structure of protein  
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tyrosine kinase pp60c-src (PDB code: 1skj),23 which is a c-src tyrosine kinase of Rous sarcoma virus, was used in 
this docking study. The 3D structure of 1skj was reported by Plummer et al.23 using X-ray diffraction technique 
with a resolution of 2.10 Å. The 1skj was retrieved from the Brookhaven protein database: 
URL*http://www.rcsb.org/pdb/Wecome.do accessed on January 10, 2006, as a complex bound with the inhibitor 
ur2: 4-[3-carboxymethyl-3-(4-phosphonooxybenzyl)ureido]-4-[(3-cyclohexylpropyl)-methylcarbamoyl]butyric 
acid. For the docking study, water molecules and ur2 ligand were removed from the protein, then the polar 
hydrogens and united atom Kollman charges were assigned for the protein. Then, various inhibitors were docked 
within the prepared protein (1skj). The mode of interaction of ur2 ligand against 1skj tyrosine was used a standard 
docked model, the one used for the calculation of the root mean square deviation (RMSD) of the docked 
inhibitors.  
 
4.4.1. Docking parameters 
Prior to the AutoDock, AutoGrid was carried out for the preparation of the grid map using a grid box with a npts 
(number of points in xyz) of 60–60–60 Å box and 120–120–120 Å box, which encloses the original ligand ur2. 
The box spacing was 0.3 Å and grid center was designated at dimensions (x, y, z): –5.143, 62.487 and –8.776. A 
scoring grid was calculated from the original ligand structure (ur2) to minimize the computation time. Finally 
AutoDock was run using maximum number of retries and generations of 10,000 and 27,000, respectively. The 
genetic algorithm with local search (GALS) was used for calculation of the docking possibilities. The complexes 
obtained by AutoDock were minimized using a maximum 300 iterations and the hybrid GALS runs with max of 
250 cycles using different random number seeds to obtain score convergence. 
 
4.4.2. Preparation of small molecules 
ChemDraw ultra 8.0 software [Chemical Structure Drawing Standard; Cambridge Soft corporation, USA(2003)] was 
used for construction of compounds which were converted to 3D structures using Chem3D ultra 8.0 software and the 
constructed 3D structures were energetically minimized by using MOPAC (semi-empirical quantum mechanics) with 
AM1 mozyme geometry, 100 iterations and minimum RMS gradient of 0.10. 
 
4.4.3. Evaluation of docked results  
Accelrys DS modeling 1.5 software [DS modeling 1.5; Accelrys inc., San Diego, CA (2003)] was utilized for 
molecular modeling for the evaluation of hydrogen bonds in ligand-receptor interaction. The correct hydrogen 
bonds were considered if their geometry angle within 110-180o acccording to Murray-Rust, et al.24 While the false 
hydrogen bonds between N-oxide moiety and Cys42 were omitted because the bond angles were less than 90o 
which are not matched with the considered parameters. Also DS modeling was used for measurement of RMSD, 
which was computed and expressed in Å as a structural comparison of two molecules in terms of distance. That is, 
it was measured as distance between the centroid of the docked inhibitor and the original ur2 ligand.  
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